Sinco Pharmaceuticals Holdings Ltd. (HK:6833)
:6833
Want to see HK:6833 full AI Analyst Report?
Top Page
Sinco Pharmaceuticals Holdings Ltd.
(6833)
Select Model
Select Model
Rating:58Neutral
Price Target:
HK$0.19
▲(3.89% Upside)
Action:ReiteratedDate:04/25/26
The score is held back primarily by weakened financial performance (sharp revenue decline and very thin margins) and historically volatile cash generation, partially offset by an improving, manageable balance sheet and a recent cash-flow rebound. Technicals are neutral overall, while the low P/E and modest dividend provide valuation support.
Positive Factors
Improving balance sheet
Debt-to-equity falling to ~0.26 from ~0.53 signals materially lower leverage and improved solvency. That provides durable financial flexibility across the next several quarters to absorb shocks, finance targeted capex or working-capital needs and reduce refinancing risk without altering core operations.
Negative Factors
Sharp revenue decline
An ~18% revenue drop reverses prior growth and reduces operating scale, which can erode bargaining power and fixed-cost absorption. Persistent top-line contraction over several quarters would strain margins, capex plans and growth initiatives, making recovery and strategic investment harder over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving balance sheet
Debt-to-equity falling to ~0.26 from ~0.53 signals materially lower leverage and improved solvency. That provides durable financial flexibility across the next several quarters to absorb shocks, finance targeted capex or working-capital needs and reduce refinancing risk without altering core operations.
Read all positive factors
Sinco Pharmaceuticals Holdings Ltd. (6833) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$384.22M
Dividend Yield1.12%
Average Volume (3M)210.00K
Price to Earnings (P/E)9.5
Beta (1Y)0.20
Revenue Growth-26.20%
EPS Growth-17.41%
CountryHK
Employees291
SectorHealthcare
Sector Strength45
IndustryAdvertising Agencies
Share Statistics
EPS (TTM)0.01
Shares Outstanding2,032,890,600
10 Day Avg. Volume85,200
30 Day Avg. Volume210,000
Financial Highlights & Ratios
PEG Ratio-0.49
Price to Book (P/B)0.47
Price to Sales (P/S)0.16
P/FCF Ratio2.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sinco Pharmaceuticals Holdings Ltd. Business Overview & Revenue Model
Company Description
Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. The company offers Octapharma, a human albumin...
Sinco Pharmaceuticals Holdings Ltd. Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
64
Positive
Cash Flow
52
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.03B | 2.82B | 2.54B | 2.27B | 2.02B |
| Gross Profit | 213.34M | 299.94M | 323.28M | 305.87M | 364.95M |
| EBITDA | 97.49M | 132.60M | 126.01M | 109.01M | 197.69M |
| Net Income | 33.95M | 42.05M | 42.35M | 69.46M | 135.08M |
Balance Sheet | |||||
| Total Assets | 1.85B | 2.00B | 1.89B | 1.42B | 1.23B |
| Cash, Cash Equivalents and Short-Term Investments | 374.53M | 308.32M | 437.92M | 329.14M | 326.05M |
| Total Debt | 183.47M | 350.54M | 251.40M | 192.41M | 340.95M |
| Total Liabilities | 1.15B | 1.34B | 1.26B | 820.52M | 857.88M |
| Stockholders Equity | 694.36M | 662.88M | 628.05M | 603.81M | 374.89M |
Cash Flow | |||||
| Free Cash Flow | 159.71M | -268.05M | 289.16M | 22.39M | 282.19M |
| Operating Cash Flow | 169.49M | -232.88M | 353.70M | 75.08M | 305.71M |
| Investing Cash Flow | -27.09M | -52.87M | -63.63M | -119.27M | -22.73M |
| Financing Cash Flow | -197.24M | 154.59M | -189.73M | 35.04M | -97.11M |
Sinco Pharmaceuticals Holdings Ltd. Technical Analysis
Positive
0.18
Price Trends
0.18
Positive
0.18
Positive
0.20
Negative
Market Momentum
>-0.01
Positive
51.59
Neutral
51.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6833, the sentiment is Positive. The current price of 0.18 is above the 20-day moving average (MA) of 0.18, above the 50-day MA of 0.18, and below the 200-day MA of 0.20, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 51.59 is Neutral, neither overbought nor oversold. The STOCH value of 51.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6833.
Sinco Pharmaceuticals Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | HK$2.58B | -21.51 | -23.25% | ― | 106.79% | -92.42% | |
58 Neutral | HK$384.22M | 9.52 | 5.03% | 1.12% | -26.20% | -17.41% | |
57 Neutral | HK$2.98B | 19.79 | 4.13% | ― | 63.98% | 2262.50% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$900.87M | -115.92 | -2.57% | ― | 9.84% | 86.09% | |
39 Underperform | HK$267.77M | -21.81 | ― | ― | -14.23% | ― |
* Healthcare Sector Average
HK:6833
Sinco Pharmaceuticals Holdings Ltd.
0.19
0.01
7.39%
HK:1762
Wanka Online, Inc.
1.52
0.87
133.85%
HK:1993
Asiaray Media Group Ltd.
0.56
-0.32
-36.36%
HK:0205
SEEC Media Group Limited
0.72
0.60
500.00%
HK:2131
Netjoy Holdings Limited
0.46
0.00
0.00%
HK:2422
Rego Interactive Co., Ltd.
1.57
1.16
282.93%
Sinco Pharmaceuticals Holdings Ltd. Corporate Events
Sinco Pharmaceuticals Sets 2026 AGM to Approve Dividend, Board Mandates and New Share-Issuance Authority
Apr 20, 2026
Sinco Pharmaceuticals Holdings Limited has called its annual general meeting for 15 May 2026 in Chengdu, where shareholders will review and adopt the audited consolidated financial statements for the year ended 31 December 2025 and the related dir...
Sinco Pharmaceuticals Updates Final Dividend for 2025 Financial Year
Mar 27, 2026
Sinco Pharmaceuticals Holdings Limited, a Hong Kong-listed pharmaceutical company trading under stock code 06833, operates within the healthcare sector and is subject to oversight and disclosure requirements of the Hong Kong Exchanges and Clearing...
Sinco Pharmaceuticals Profit Slips on Weaker Albumin Sales, Dividend Cut
Mar 26, 2026
Sinco Pharmaceuticals reported a sharp 26.1% drop in 2025 revenue to RMB2.08 billion, driven mainly by a significant decline in sales volume of its core human albumin solution product. Despite the revenue contraction, the group maintained a broadl...
Sinco Pharmaceuticals Declares Final Dividend for 2025 Financial Year
Mar 26, 2026
Sinco Pharmaceuticals Holdings Limited has proposed a final ordinary cash dividend of HKD 0.167 per share for the financial year ended 31 December 2025, subject to shareholder approval at a meeting scheduled for 15 May 2026. The dividend will be p...
Sinco Pharmaceuticals Sets March Board Meeting to Approve 2025 Results and Consider Final Dividend
Mar 16, 2026
Sinco Pharmaceuticals Holdings Limited has scheduled a board meeting for 26 March 2026 to review and approve the annual results of the company and its subsidiaries for the financial year ended 31 December 2025. The board will also consider the pos...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.